Oncology
From the Journals
Managing trastuzumab deruxtecan adverse events in the real world
Doctor says real-world toxicity experience has been worse than clinical trial data.
News
FDA rejects poziotinib for certain types of lung cancer
The clinical data the company submitted was deemed insufficient for approval.
Conference Coverage
Lung cancer screening pushes 20-year survival rate to 80%
Less than 6% of high-risk smokers get the recommended annual lung cancer screening.
News
Atezolizumab (Tecentriq) bladder cancer indication withdrawn in United States
The anti-PD-L1 inhibitor continues to be approved for lung and liver cancers and melanoma.
Conference Coverage
Whole breast radiation for breast cancer shown to be safe and effective
Whole breast radiation can cut treatment time from 6 weeks down to 3 weeks.
Latest News
Consider radiologic imaging for high-risk cutaneous SCC, expert advises
Surgery may be the mainstay of treatment for resectable SCC, but the emerging role of neoadjuvant therapeutics is changing the way oncologists...
Conference Coverage
Immunotherapy may be path forward in HPV oropharyngeal cancer
Immunotherapy benefits locally advanced HPV-positive oropharyngeal cancer in phase 2 study.
Conference Coverage
Latinx and melanoma: Barriers and opportunities
A qualitative study in California reveals challenges and attitudes that could be addressed with new melanoma outreach and prevention strategies....
Conference Coverage
Stage 3 melanoma attacked with immunotherapy and a virus-like particle
Phase 2 trial achieves some success, and responders had infiltrate of plasmacytoid dendritic cells.
Conference Coverage
Stool transplants may boost immunotherapy success in melanoma
A phase 1 trial shows good clinical response after transplants from healthy donors.
Conference Coverage
Immunotherapeutic target could fill unmet need in NSCLC
Phase 2 clinical trial shows consistent benefits at all levels of PD-L1 expression.